Maria Novella Romanelli

Prof. Maria Novella Romanelli

Department of Neuroscience, Psychology, Drug Research and Child’s Health, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2017 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
LSLaura Sartiani
Laura Sartiani
GMGuido Mannaioni
Guido Mannaioni
AMAlessio Masi
Alessio Masi
MRMaria Novella Romanelli
Maria Novella Romanelli
ECElisabetta Cerbai
Elisabetta Cerbai
Hyperpolarization-activated, cyclic nucleotide–gated (HCN) channels are important members of the voltage-gated pore loop channels family. They show unique features: they open at hyperpolarizing potential, carry a mixed Na/K current, and are regulated by cyclic nucleotides. Four different isoforms have been cloned (HCN1–4) that can assemble to form homo- or heterotetramers, characterized by different biophysical properties. These proteins are widely distributed throughout the body and involved in different physiologic processes, the most important being the generation of spontaneous electrical activity in the heart and the regulation of synaptic transmission in the brain. Their role in heart rate, neuronal pacemaking, dendritic integration, learning and memory, and visual and pain perceptions has been extensively studied; these channels have been found also in some peripheral tissues, where their functions still need to be fully elucidated. Genetic defects and altered expression of HCN channels are linked to several pathologies, which makes these proteins attractive targets for translational research; at the moment only one drug (ivabradine), which specifically blocks the hyperpolarization-activated current, is clinically available. This review discusses current knowledge about HCN channels, starting from their biophysical properties, origin, and developmental features, to (patho)physiologic role in different tissues and pharmacological modulation, ending with their present and future relevance as drug targets.

31 May 2007 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
MRMaria Novella Romanelli
Maria Novella Romanelli
Paola GratteriPaola Gratteri
Paola Gratteri
LGLuca Guandalini
Luca Guandalini
EMElisabetta Martini
Elisabetta Martini
CBClaudia Bonaccini
Claudia Bonaccini
FGFulvio Gualtieri
Fulvio Gualtieri

4 January 1996 in Nature
Verified
Journal Article
Closed access
PDPiero Dolara
Piero Dolara
Cristina LuceriCristina Luceri
Cristina Luceri
CGcarla ghelardini
carla ghelardini
CMClaudia Monserrat
Claudia Monserrat
SASilvia Aiolli
Silvia Aiolli
MRMaria Novella Romanelli
Maria Novella Romanelli

27 March 2003 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
MRMaria Novella Romanelli
Maria Novella Romanelli
FGFulvio Gualtieri
Fulvio Gualtieri

29 April 2016 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Open access
MRMaria Novella Romanelli
Maria Novella Romanelli
LSLaura Sartiani
Laura Sartiani
AMAlessio Masi
Alessio Masi
GMGuido Mannaioni
Guido Mannaioni
DMDina Manetti
Dina Manetti
ECElisabetta Cerbai
Elisabetta Cerbai
Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels, the molecular correlate of the hyperpolarization-activated current (If/Ih), are membrane proteins which play an important role in several physiological processes and various pathological conditions. In the Sino Atrial Node (SAN) HCN4 is the target of ivabradine, a bradycardic agent that is, at the moment, the only drug which specifically blocks If. Nevertheless, several other pharmacological agents have been shown to modulate HCN channels, a property that may contribute to their therapeutic activity and/or to their side effects. HCN channels are considered potential targets for developing drugs to treat several important pathologies, but a major issue in this field is the discovery of isoform-selective compounds, owing to the wide distribution of these proteins into the central and peripheral nervous systems, heart and other peripheral tissues. This survey is focused on the compounds that have been shown, or have been designed, to interact with HCN channels and on their binding sites, with the aim to summarize current knowledge and possibly to unveil useful information to design new potent and selective modulators.

1 January 2002 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
FGFulvio Gualtieri
Fulvio Gualtieri
DMDina Manetti
Dina Manetti
MRMaria Novella Romanelli
Maria Novella Romanelli
CGcarla ghelardini
carla ghelardini
Cognition enhancers are drugs able to facilitate attentional abilities and acquisition, storage and retrieval of information, and to attenuate the impairment of cognitive functions associated with head traumas, stroke, age and age-related pathologies. Development of cognition enhancers is still a difficult task because of complexity of the brain functions, poor predictivity of animal tests and lengthy and expensive clinical trials. After the early serendipitous discovery of first generation cognition enhancers, current research is based on a variety of working hypotheses, derived from the progress of knowledge in the neurobiopathology of cognitive processes. Among other classes of drugs, piracetam-like cognition enhancers (nootropics) have never reached general acceptance, in spite of their excellent tolerability and safety. In the present review, after a general discussion of the problems connected with the design and development of cognition enhancers, the class is examined in more detail. Reasons for the problems encountered by nootropics, compounds therapeutically available and those in development, their structure activity relationships and mechanisms of action are discussed. Recent developments which hopefully will lead to a revival of the class are reviewed.